Серьезные коморбидные инфекции у пациентов с воспалительными заболеваниями суставов: частота, структура, факторы риска

Серьезные коморбидные инфекции (СКИ) – инфекции, развивающиеся на фоне основного заболевания и требующие госпитализации и/или внутривенного введения антибактериальных препаратов. В структуре коморбидной инфекционной патологии у пациентов с воспалительными заболеваниями суставов (ВЗС) на долю СКИ приходится не более 4%. Однако именно они являются непосредственной причиной смерти этих пациентов. Развитию СКИ у пациентов с ВЗС способствуют различные факторы, в том числе социальнодемографические, а также связанные непосредственно с самим ВЗС, включая проводимую терапию.

В статье рассматриваются частота, структура, факторы риска СКИ у пациентов с ВЗС.

1. Germano V, Cattaruzza MS, Osborn J, et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticoster-oids and TNF- antagonists. J Transl Med. 2014 Mar 22:12:77. doi: 10.1186/1479-5876-12-77.

2. Pinheiro FA, Souza DC, Sato EI. A Study of Multiple Causes of Death in Rheumatoid Arthritis. J Rheumatol. 2015 Dec;42(12): 2221-8. doi: 10.3899/jrheum.150166. Epub 2015 Oct 15.

3. Choi IA, Lee JS, Song YW, Lee EY. Mortality, disability, and healthcare expenditure of patients with seropositive rheumatoid arthritis in Korea: A nationwide populationbased study. PLoS One. 2019 Jan 8;14(1): e0210471. doi: 10.1371/journal.pone.0210471.

4. Aureal M, Seauve M, Laplane S, et al. Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies. RMD Open. 2023 Sep;9(3):e003064. doi: 10.1136/rmdopen-2023-003064.

5. Yamanaka H, Askling J, Berglind N, et al. Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. RMD Open. 2017 Oct 10;3(2):e000498. doi: 10.1136/rmdopen-2017-000498.

6. Thomas K, Lazarini A, Kaltsonoudis E, et al. Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. Rheumatology (Oxford). 2021 May 14;60(5):2223-2230. doi: 10.1093/rheumatology/keaa557.

7. Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012 Dec; 12(2):225-9. doi: 10.1016/j.autrev.2012.06.008.

8. Atzeni F, Sarzi-Puttini P, Sebastiani M, et al. Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. Clin Exp Rheumatol. 2019 Jul-Aug;37(4):649-655. Epub 2019 Feb 11.

9. Mehta B, Pedro S, Ozen G, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019 Jun 9;5(1): e000935. doi: 10.1136/rmdopen-2019-000935.

10. Wallis D, Thavaneswaran A, Haroon N, et al. Tumour necrosis factor in-hibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort. Rheumatology (Oxford). 2015 Jan;54(1): 152-6. doi: 10.1093/rheumatology/keu255. Epub 2014 Aug 13.

11. Sharma C, Keen H. Ten-year retrospective review of the incidence of serious infections in patients on biologic disease modifying agents for rheumatoid arthritis in three tertiary hospitals in Western Australia. Intern Med J. 2019 Apr;49(4):519-525. doi: 10.1111/imj.14109.

12. Burmester GR, Gordon KB, Rosenba um JT, et al. Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Adv Ther. 2020 Jan;37(1):364-380. doi: 10.1007/s12325-019-01145-8.

13. Dixon WG, Watson K, Lunt M, et al. British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006 Aug;54(8):2368-76. doi: 10.1002/art.21978.

14. Taylor PC, Atzeni F, Balsa A, et al. The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. J Clin Med. 2021 Feb 1;10(3):509. doi: 10.3390/jcm10030509.

15. Accortt NA, Lesperance T, Liu M, et al. Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2018 May;70(5):679-684. doi: 10.1002/acr.23426.

16. Moura CS, Rahme E, Maksymowych WP, et al. Use of disease-modifying anti-rheumatic or anti-tumour necrosis factor drugs and risk of hospitalized infection in ankylosing spondylitis. Scand J Rheumatol. 2019 Mar;48(2): 121-127. doi: 10.1080/03009742.2018.1470253. Epub 2018 Aug 16.

17. Roubille C, Coffy A, Rincheval N, et al. Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford). 2021 Aug 2;60(8):3738-3746. doi: 10.1093/rheumatology/keaa850.

18. George MD, Baker JF, Winthrop K, et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a Cohort study. Ann Intern Med. 2020 Dec 1;173(11):870-878. doi: 10.7326/M20-1594. Epub 2020 Sep 22.

19. Atzeni F, Masala IF, di Franco M, Sarzi-Puttini P. Infections in rheumatoid arthritis. Curr Opin Rheumatol. 2017 Jul;29(4):323-330. doi: 10.1097/BOR.0000000000000389.

20. Hashimoto A, Suto S, Horie K, et al. Incidence and Risk Factors for Infections Requiring Hospitalization, Including Pneumocystis Pneumonia, in Japanese Patients with Rheumatoid Arthritis. Int J Rheumatol. 2017:2017:6730812. doi: 10.1155/2017/6730812. Epub 2017 Oct 18.

21. Quartuccio L, Zabotti A, Del Zotto S, et al. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data. J Adv Res. 2018 Sep 19;15:87-93. doi: 10.1016/j.jare.2018.09.003.

22. Frisell T, Bower H, Morin M, et al. Safety of biological and targeted synthetic diseasemodifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Ann Rheum Dis. 2023 May;82(5):601-610. doi: 10.1136/ard-2022-223762.

23. Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017 Jun;76(6):1101-1136. doi: 10.1136/annrheumdis-2016-210708.

24. Liao H, Zhong Z, Liu Z, Zou X. Compa rison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis. 2017 Feb;20(2):161-168. doi: 10.1111/1756-185X.12970.

25. Sepriano A, Kerschbaumer A, Bergstra SA, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023 Jan;82(1):107-118. doi: 10.1136/ard-2022-223357.

26. Chen SK, Liao KP, Liu J, et al. Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study. Arthritis Care Res (Hoboken). 2020 Jan;72(1): 9-17. doi: 10.1002/acr.23824. Epub 2019 Nov 29.

27. Chen HH, Lin CH, Wang CY, et al. Association of hospitalised infection with socioeconomic status in patients with rheumatoid arthritis receiving biologics or tofacitinib: a population-basedcohort study. Front Med (Lausanne). 2021 Jul 12;8:696167. doi: 10.3389/fmed.2021.696167.

28. Grøn KL, Glintborg B, Nørgaard M, et al. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study. Rheumatology (Oxford). 2020 Aug 1; 59(8):1949-1956. doi: 10.1093/rheumatology/kez530.

29. Jeon HL, Kim SC, Park SH, Shin JY. The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea. Semin Arthritis Rheum. 2021 Oct;51(5): 989-995. doi: 10.1016/j.semarthrit.2021.07.004. Epub 2021 Jul 8.

30. Kremer JM, Bingham CO, Cappelli LC, et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States- based rheumatoid arthritis registry. ACR Open Rheumatol. 2021 Mar;3(3): 173-184. doi: 10.1002/acr2.11232. Epub 2021 Feb 11.

31. Montastruc F, Renoux C, Hudson M, et al. Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study. Semin Arthritis Rheum. 2019 Jun;48(6):1053-1058. doi: 10.1016/j.semarthrit.2019.01.009. Epub 2019 Jan 25.

32. Ozen G, Pedro S, Schumacher R, et al. Safety of abatacept compared with other biologic and conventional synthetic diseasemodifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study. Arthritis Res Ther. 2019 Jun 7; 21(1):141. doi: 10.1186/s13075-019-1921-z.

33. Pawar A, Desai RJ, Gautam N, Kim SC. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatol. 2020 Feb;2(2):e84-e98. doi: 10.1016/S2665-9913(19)30137-7.

34. Patel V, Pulungan Z, Shah A, et al. Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying antirheumatic drugs. J Med Econ. 2021 Jan-Dec; 24(1):299-307. doi: 10.1080/13696998.2021.1881525.

35. Simon TA, Boers M, Hochberg M, et al. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. Arthritis Res Ther. 2019 Nov 8;21(1):228. doi: 10.1186/s13075-019-1992-x.

36. Cohen S, Radominski SC, Gomez-Rei no JJ, et al. Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2014 Nov;66(11):2924-37. doi: 10.1002/art.38779.

37. Smolen JS, Genovese MC, Takeuchi T, et al. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with Over 2 Years Median Time in Treatment. J Rheumatol. 2019 Jan;46(1):7-18. doi: 10.3899/jrheum.171361. Epub 2018 Sep 15.

38. Almanzar G, Kienle F, Schmalzing M, et al. Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis. Rheumatology (Oxford). 2019 Nov 1;58(11):2051-2060. doi: 10.1093/rheumatology/kez175. PMID: 31106368.

39. Atzeni F, Talotta R, Nucera V, et al. Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert Rev Clin Immunol. 2018 Nov;14(11): 945-956. doi: 10.1080/1744666X.2018.1504678. Epub 2018 Aug 21.

40. Буханова ДВ, Белов БС, Тарасова ГМ и др. Коморбидные инфекции при ревматических заболеваниях (по данным ФГБНУ НИИР им. В.А. Насоновой). Медицинский Совет. 2019;(9):86-91.

41. Баранова ММ, Муравьева НВ, Белов БС и др. Коморбидные инфекции у больных спондилоартритами: частота, структура, факторы риска. Современная ревматология. 2023;17(4):64-70. doi: 10.14412/1996-7012-2023-4-64-70.